AFFLUENT MEDICAL announces that it has successfully implanted at the Vienna General Hospital, Austria, the first adjustable Kalios ring, intended to restore the normal functioning of the mitral valve with closing defects in some patients.
KALIOS is the first fully adjustable mitral valve repair device, designed to effectively meet the needs of patients with mitral insufficiency, which affects 1% of the world’s population.
KALIOS can treat both residual postoperative leaks and chronic mitral insufficiency. The size and shape of the implant can be adjusted percutaneously multiple times in the months/years following the surgery, offering patients a personalized surgical treatment. The European launch of this device, currently in human clinical trial in Europe, is scheduled for the end of 2020. It targets a global market expected to reach $3.5 billion by 2022 and growing at a rate of 35% per year between 2017-2022.